Increased MYC Gene Copy Number Correlates with Increased MRNA Levels in Diffuse Large B-cell Lymphoma
Overview
Authors
Affiliations
Background: Translocations involving the MYC gene and increased MYC mRNA levels are associated with poor outcome in diffuse large B-cell lymphoma. However, the presence of increased MYC gene copy number and/or polysomy of chromosome 8 have not been previously described.
Design And Methods: Utilizing dual color chromogenic in situ hybridization, we investigated MYC gene copy and chromosome 8 centromere numbers in 52 cases of diffuse large B-cell lymphoma. Cases were divided into those with "increased" or "not increased" MYC gene copy number for comparison with MYC mRNA levels, Ki-67 values, and survival.
Results: Increased MYC gene copy number was present in 38% of cases. Overall, the average MYC mRNA level was 2398 (range, 342 - 9783) and the percentage of nuclei positive for Ki-67 was 57.5% (range, 20-87%). Within the group with increased MYC copy number, the MYC mRNA values ranged from 816 to 5912 (average, 2843) and the Ki-67 values ranged from 23% to 83% (average, 57%). Within the group with not increased MYC copy number, MYC mRNA values ranged from 342 to 9783 (average, 2118) and the Ki-67 values ranged from 20% to 87% (average, 58%). There was a statistically significant relationship between increased MYC gene copy number and increased MYC mRNA (P=0.034) and a trend toward a relationship between increased mRNA and higher Ki-67 values.
Conclusions: This is the first report that low level copy number increases are common in diffuse large B-cell lymphoma and that these changes correlate with MYC mRNA in a statistically significant manner. MYC copy number changes are an additional possible molecular mechanism that may result in increased mRNA and, likely, high proliferation and poor outcome.
Papaleo N, Molina-Alvarez A, Onieva R, Fuertes D, Sanchez-Gonzalez B, Riera X Cancers (Basel). 2024; 16(13).
PMID: 39001439 PMC: 11240605. DOI: 10.3390/cancers16132378.
Wang Y, Liu D, Zhang X, Zhang M, Li S, Feng X Cancer Med. 2023; 12(18):18568-18577.
PMID: 37641492 PMC: 10557898. DOI: 10.1002/cam4.6463.
Suzuki S, Kuwamoto S, Kawamura K, Matsushita M, Motokura T, Hosoda Y Yonago Acta Med. 2023; 66(1):56-66.
PMID: 36820285 PMC: 9937959. DOI: 10.33160/yam.2023.02.007.
Altered pathways and targeted therapy in double hit lymphoma.
Zhuang Y, Che J, Wu M, Guo Y, Xu Y, Dong X J Hematol Oncol. 2022; 15(1):26.
PMID: 35303910 PMC: 8932183. DOI: 10.1186/s13045-022-01249-9.
Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies.
Salles D, Vidotto T, Faisal F, Tosoian J, Guedes L, Muranyi A J Mol Diagn. 2021; 23(8):1030-1041.
PMID: 34062284 PMC: 8491088. DOI: 10.1016/j.jmoldx.2021.05.006.